MedNet Solutions Partners with Heart Imaging Technologies
MedNet Solutions, a global life sciences technology company specializing in clinical study management systems, and Heart Imaging Technologies (Heart IT), an industry leader in web-based medical image viewing and management solutions, are pleased to announce their strategic partnership and the integration of Heart IT?s WebPAX technology with MedNet?s eClinical solutions.
MedNet Solutions
, a global life sciences technology company specializing in clinical study management systems, and
Heart Imaging Technologies (Heart IT)
, an industry leader in web-based medical image viewing and management solutions, are pleased to announce their strategic partnership and the integration of Heart IT’s
WebPAX®
technology with MedNet’s
eClinical solutions
. This integration greatly improves the speed, accuracy and efficiency of clinical trials that rely on the collection and analysis of DICOM images.
"We are very pleased with our new partnership,” stated Dr. Robert M. Judd, President for Heart IT. “MedNet is a leader in the EDC industry and their applications allow their customers to greatly improve the efficiency of their clinical trials. In many studies, medical images play a critical role. By embedding our application within MedNet's eClinical offerings, we’re able to provide MedNet's customers with a complete end-to-end solution to acquire, transmit and effectively manage all of the medical images associated within any given trial. The best part is that our imaging component is completely web-based and zero-footprint: It does not require the user to download any software to view the images. This new process is a quantum leap ahead of the current manual processes which are both time-consuming and inefficient.”
“We’re excited to offer WebPAX as a value-added option within both our
iMedNet™ EDC
and
ENLIGHTEN®
solutions,” noted John M. (Rob) Robertson, President and CEO of MedNet Solutions. “Integrating WebPAX offers our customers numerous advantages, including easy image uploading; immediate and secure worldwide image access by sites, core labs, CROs and sponsors; and superior image viewing from within our cloud-based EDC and study management solutions.”
For more information, please contact MedNet Solutions.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
